LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Home・Akcijų sąrašas・Innoviva Inc

Innoviva Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

22.41 1.17

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

22.38

Max

22.75

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-55M 187M
Pardavimai	-20M 98M
P/E Sektoriaus vid.	3.436 49.888
Pelnas, tenkantis vienai akcijai	0.47
Pelno marža	190.415
Darbuotojai	159
EBITDA	-160M 48M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+55.69% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-04

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-115M 1.6B
Ankstesnė atidarymo kaina	21.24
Ankstesnė uždarymo kaina	22.41

Naujienos nuotaikos

By Acuity

21%

79%

48 / 344 reitingas Healthcare

Innoviva Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-05 19:20; UTC

Pagrindinės rinkos jėgos

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

2026-06-05 21:27; UTC

Uždarbis

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

2026-06-05 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-06-05 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-05 20:20; UTC

Įsigijimai, susijungimai, perėmimai

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

2026-06-05 20:19; UTC

Įsigijimai, susijungimai, perėmimai

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

2026-06-05 20:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-06-05 19:26; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-05 19:26; UTC

Rinkos pokalbiai

Hog Futures Tumble to Close Week -- Market Talk

2026-06-05 19:10; UTC

Rinkos pokalbiai

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

2026-06-05 19:03; UTC

Rinkos pokalbiai

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

2026-06-05 18:59; UTC

Rinkos pokalbiai

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

2026-06-05 18:47; UTC

Rinkos pokalbiai

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

2026-06-05 18:34; UTC

Rinkos pokalbiai

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

2026-06-05 18:33; UTC

Įsigijimai, susijungimai, perėmimai

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

2026-06-05 17:50; UTC

Uždarbis

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

2026-06-05 17:27; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

2026-06-05 16:48; UTC

Įsigijimai, susijungimai, perėmimai

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

2026-06-05 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-06-05 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-06-05 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-06-05 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-06-05 15:44; UTC

Įsigijimai, susijungimai, perėmimai

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

2026-06-05 15:26; UTC

Rinkos pokalbiai

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

2026-06-05 15:25; UTC

Uždarbis

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

2026-06-05 15:16; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-05 15:16; UTC

Rinkos pokalbiai

Zcash Tumbles After Exploit Found -- Market Talk

2026-06-05 15:09; UTC

Rinkos pokalbiai

Canada's May Jobs Report Underscores Volatility Worries Over Data Collection -- Market Talk

2026-06-05 15:07; UTC

Rinkos pokalbiai

Canada's Economy Still Has Legs With Total Employment Close to Record -- Market Talk

2026-06-05 15:05; UTC

Rinkos pokalbiai

Canada's Labor-Market Weakness to Start 2026 Likely 'Overstated' -- Market Talk

Akcijų palyginimas

Kainos pokytis

Innoviva Inc Prognozė

Kainos tikslas

By TipRanks

55.69% į viršų

12 mėnesių prognozė

Vidutinis 34.5 USD 55.69%

Aukščiausias 46 USD

Žemiausias 18 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Innoviva Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Innoviva Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

48 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.